Growth outlook in pharma looks better than IT: Purushottam

Sangeeta Purushottam, Professional Investor told CNBC-TV18, "In pharmaceutical space, one is a little less concerned about growth as compared to IT. Of course, pharma is also a fairly company specific story given the complexities of addressing particularly the US market, but on the whole the growth outlook in pharma is better than IT."

At 10:06 hours IST, Ranbaxy Laboratories was quoting at Rs 356.10, up Rs 3.70, or 1.05 percent. It has touched an intraday high of Rs 357.60 and an intraday low of Rs 349.
The company's trailing 12-month (TTM) EPS was at Rs 5.32 per share. (Mar, 2013). The stock's price-to-earnings (P/E) ratio was 67.01. The latest book value of the company is Rs 45.40 per share. At current value, the price-to-book value of the company was 7.85.